Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
코로나19 폐렴 환자를 위한 토실리주맙. 단일군 TOCIVID-19 전향적 시험
Research
[키워드] Analysis
baseline
blocks pro-inflammatory activity
cause of death
co-primary endpoints
Cohort
coronavirus
COVID-19
COVID-19 patients
dataset
death
death in COVID-19
drug toxicity
effective
enrolled
EudraCT
evaluated
expected
exploratory
greater
IL-6
intention-to-treat
Interaction
interleukin
interleukin-6
involved
ITT
lethality rate
lethality rates
mechanical respiratory
Mortality
multicenter
multivariable logistic regression
NCT04317092
negatively affected
null hypothesis
Older age
PaO2/FiO2 ratio
Pathogenesis
Patient
patients
patients with COVID-19
Phase 2
Pneumonia
pro-inflammatory activity
prognostic variable
prognostic variables
prospective cohort
Prospective trial
reduced
Registration
reported
respiratory
Respiratory Support
Result
Safety
single-arm
statistically significant
Steroids
subject
Support
survival
Tocilizumab
TOCIVID-19
Toxicity
Trial
use of steroid
was used
[DOI] 10.1186/s12967-020-02573-9 PMC 바로가기 [Article Type] Research
[DOI] 10.1186/s12967-020-02573-9 PMC 바로가기 [Article Type] Research